Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.38 |
| ▸ | CBLB | Q13191 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16561403 | 0.97 | PCSK9 (0.37) | PCSK9CBLBCYP3A4IRAK4MAP3K7 | |
| SCHEMBL16561406 | 0.80 | IRAK4 (0.34) | IRAK4ALDH1A1 | |
| SCHEMBL16561388 | 0.77 | IRAK4 (0.34) | IRAK4ALDH1A1 | |
| SCHEMBL16561386 | 0.76 | AAK1 (0.56) | IRAK4 | |
| SCHEMBL16561392 | 0.73 | AAK1 (0.55) | IRAK4 | |
| SCHEMBL10127403 | 0.70 | HDAC1 (0.52) | — | |
| SCHEMBL5872614 | 0.70 | KCNH2 (0.51) | — | |
| SCHEMBL23529908 | 0.64 | DYRK1A (0.44) | PCSK9CBLBIRAK4KDM4ENAMPT | |
| SCHEMBL6468289 | 0.64 | DYRK1A (0.44) | PCSK9CBLBIRAK4NAMPT | |
| SCHEMBL3347070 | 0.64 | DYRK1A (0.44) | PCSK9NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041475-B1 | PYRAZOLO[1,5-A]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-10118941-B2 | Methods for the preparation of diastereomerically pure phosphoramidate prodrugs | MEDIVIR AB (SE) | 2018-11-06 | — | — | US | disclosed |
| US-10106571-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2018-10-23 | — | — | US | disclosed |
| US-20180105549-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2018-04-19 | — | — | US | disclosed |
| US-20180036330-A1 | NUCLEOTIDE PHOSPHORAMIDATE FORMULATION | MEDIVIR AB (SE) | 2018-02-08 | — | — | US | disclosed |
| US-9862724-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9862724-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170275322-A1 | METHODS FOR THE PREPARATION OF DIASTEREOMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | MEDIVIR AB (SE) | 2017-09-28 | — | — | US | disclosed |
| US-20170081330-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-03-23 | — | — | US | disclosed |
| US-20170081330-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-03-23 | — | — | US | disclosed |
| US-9540411-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2017-01-10 | — | — | US | disclosed |
| US-20160340380-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-9481703-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2016-11-01 | — | — | US | disclosed |
| EP-3041475-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| US-20150175610-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175610-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175610-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| WO-2015035117-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035117-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106571-B2 | HCV polymerase inhibitors | POLI, POLB, POLL | PCSK9 1899/4885CBLB 4137/4885CYP3A4 817/4885 |
| US-20180036330-A1 | NUCLEOTIDE PHOSPHORAMIDATE FORMULATION | SLC29A1, SAMHD1, PRPF31 | PCSK9 4080/4885CBLB 3793/4885CYP3A4 860/4885 |
| US-20180105549-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | PCSK9 1899/4885CBLB 4137/4885CYP3A4 817/4885 |
| US-20170275322-A1 | METHODS FOR THE PREPARATION OF DIASTEREOMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | PNP, PAICS, NUDT1 | PCSK9 2905/4885CBLB 4490/4885CYP3A4 328/4885 |
| US-20170081330-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | TPX2, MAP3K1, IRAK1 | PCSK9 4238/4885CBLB 760/4885CYP3A4 4737/4885 |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | PCSK9 1899/4885CBLB 4137/4885CYP3A4 817/4885 |
| US-20150175610-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | TPX2, MAP3K1, IRAK1 | PCSK9 4238/4885CBLB 760/4885CYP3A4 4737/4885 |
| US-20160340380-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | PCSK9 1899/4885CBLB 4137/4885CYP3A4 817/4885 |
| US-10118941-B2 | Methods for the preparation of diastereomerically pure phosphoramidate prodrugs | PNP, PAICS, NUDT1 | PCSK9 2905/4885CBLB 4490/4885CYP3A4 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.